Evidence map›Paper›PMID 31391079›Full record

ReviewSkeletal muscle2019

NAD+ improves neuromuscular development in a zebrafish model of FKRP-associated dystroglycanopathy.

Erin C Bailey, Sarah S Alrowaished, Elisabeth A Kilroy, Emma S Crooks, Daisy M Drinkert, Chaya M Karunasiri, Joseph J Belanger, Andre Khalil, Joshua B Kelley, Clarissa A Henry

Open access · goldAbstract readReview
In one paragraph

Review in Skeletal muscle, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Erin C BaileySchool of Biology and Ecology, University of Maine, Orono, ME, 04469, USA.
Sarah S AlrowaishedSchool of Biology and Ecology, University of Maine, Orono, ME, 04469, USA.
Elisabeth A KilroyGraduate School of Biomedical Sciences and Engineering, University of Maine, 217 Hitchner Hall, Orono, ME, 04469, USA.
Emma S CrooksSchool of Biology and Ecology, University of Maine, Orono, ME, 04469, USA.
Daisy M DrinkertMolecular and Biomedical Sciences, University of Maine, Orono, ME, 04469, USA.
Chaya M KarunasiriSchool of Biology and Ecology, University of Maine, Orono, ME, 04469, USA.
Joseph J BelangerSchool of Biology and Ecology, University of Maine, Orono, ME, 04469, USA.
Andre KhalilChemical and Biomedical Engineering, University of Maine, Orono, ME, 04469, USA.
Joshua B KelleyMolecular and Biomedical Sciences, University of Maine, Orono, ME, 04469, USA.
Clarissa A HenrySchool of Biology and Ecology, University of Maine, Orono, ME, 04469, USA. Clarissa.Henry@maine.edu.ORCID 0000-0001-7204-9231
University of Maine · USLake Erie College of Osteopathic Medicine · USTufts University · US

Funding

The role of G alpha signaling in gradient trackingR15GM128026 · NIGMS · UNIVERSITY OF MAINE ORONO · PI KELLEY, JOSHUA BRIAN, KHALIL, ANDRE · 2018 to 2018
$424k
Novel Mechanisms of Extracellular Matrix Regulation During DevelopmentR15HD088217 · NICHD · UNIVERSITY OF MAINE ORONO · PI HENRY, CLARISSA A · 2016 to 2016
$355k
NICHD NIH HHS R15 HD088217NIGMS NIH HHS R15 GM128026
6 · The paper itself

Abstract

backgroundSecondary dystroglycanopathies are muscular dystrophies that result from mutations in genes that participate in Dystroglycan glycosylation. Glycosylation of Dystroglycan is essential for muscle fibers to adhere to the muscle extracellular matrix (myomatrix). Although the myomatrix is disrupted in a number of secondary dystroglycanopathies, it is unknown whether improving the myomatrix is beneficial for these conditions. We previously determined that either NAD+ supplementation or overexpression of Paxillin are sufficient to improve muscle structure and the myomatrix in a zebrafish model of primary dystroglycanopathy. Here, we investigate how these modulations affect neuromuscular phenotypes in zebrafish fukutin-related protein (fkrp) morphants modeling FKRP-associated secondary dystroglycanopathy.

resultsWe found that NAD+ supplementation prior to muscle development improved muscle structure, myotendinous junction structure, and muscle function in fkrp morphants. However, Paxillin overexpression did not improve any of these parameters in fkrp morphants. As movement also requires neuromuscular junction formation, we examined early neuromuscular junction development in fkrp morphants. The length of neuromuscular junctions was disrupted in fkrp morphants. NAD+ supplementation prior to neuromuscular junction development improved length. We investigated NMJ formation in dystroglycan (dag1) morphants and found that although NMJ morphology is disrupted in dag1 morphants, NAD+ is not sufficient to improve NMJ morphology in dag1 morphants. Ubiquitous overexpression of Fkrp rescued the fkrp morphant phenotype but muscle-specific overexpression only improved myotendinous junction structure.

conclusionsThese data indicate that Fkrp plays an early and essential role in muscle, myotendinous junction, and neuromuscular junction development. These data also indicate that, at least in the zebrafish model, FKRP-associated dystroglycanopathy does not exactly phenocopy DG-deficiency. Paxillin overexpression improves muscle structure in dag1 morphants but not fkrp morphants. In contrast, NAD+ supplementation improves NMJ morphology in fkrp morphants but not dag1 morphants. Finally, these data show that muscle-specific expression of Fkrp is insufficient to rescue muscle development and homeostasis.

Indexed as

AnimalsAnimals, Genetically ModifiedDisease Models, AnimalDystroglycansGlycosylationGlycosyltransferasesHumansMuscle DevelopmentMuscular Dystrophy, AnimalMutationNADNeuromuscular JunctionPaxillinUp-RegulationZebrafishZebrafish ProteinsDAG1 protein, zebrafishDystroglycansFKRP protein, zebrafishGlycosyltransferasesNADPaxillinpxna protein, zebrafishZebrafish ProteinsDystroglycanopathyFKRPNAD+Neuromuscular junctionZebrafish

Identifiers

PMID31391079
PMCPMC6685180
OpenAlexW2965569283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.